An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

The chronic lymphocytic leukemia (CLL) care team often takes a multidisciplinary approach, with specialists and healthcare professionals collaborating to provide a comprehensive, personalized ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic lymphocytic leukemia who received 1 prior line of therapy in the first article ...

Chronic lymphocytic leukemia (CLL) is a mature B-cell hematological malignancy characterized by progressive clonal proliferation of B lymphocytes in the peripheral blood, bone marrow, and lymph nodes.

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's ...

Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on ...

Chronic lymphocytic leukemia (CLL) starts in bone marrow, the soft inner part of your bones. There are some key differences that set CLL apart from other types of leukemia, such as ALL (acute ...

If approved, the new drug may be tolerated ... A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to a study published ...

ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.

Chronic lymphocytic leukemia (CLL) is usually a slow-growing blood cancer. Most people with CLL don’t notice any problems in the early stages of the disease. “In fact, we can do what we call ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...